Market Signal Briefing

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© aydinmutlu / Getty Images

Comfort Systems USA Inc. (NYSE:FIX) has delivered a phenomenal start to 2026, surging 43% year-to-date through February 11 to reach $1,335.14. The HVAC and mechanical systems contractor has transformed from a traditional industrial stock into an AI infrastructure play, riding unprecedented demand from data center buildouts.

But with shares up 208% over the past year and trading at 54x trailing earnings, investors face a critical question: is this rally sustainable, or has the market gotten ahead of itself?

The Earnings Machine Behind the Rally Comfort Systems hasn’t reported Q4 2025 or Q1 2026 earnings yet, but the momentum stems directly from their explosive Q3 2025 results filed October 23, 2025. The company delivered revenue of $2.45 billion, crushing Wall Street’s $2.18 billion estimate by 12%. More impressive was the $8.25 earnings per share versus the $6.29 consensus, a 31% beat that doubled year-over-year results.

CEO Brian Lane captured the momentum succinctly: “unprecedented demand for our services drove additional backlog growth” and delivered “third quarter EPS that doubles our same quarter last year.” Operating cash flow surged 83% to $553.3 million, while the company’s backlog hit a record $9.38 billion with $1 billion in same-store growth.

S&P 500 Inclusion and Institutional Validation The company’s S&P 500 inclusion has catalyzed massive institutional buying. Firms like WCM Investment Management added 31,000 shares, while New York State Common Retirement Fund increased its stake 91% to 33,942 shares. With 96.51% institutional ownership, this isn’t retail speculation driving the stock higher.

Analyst support has strengthened alongside institutional interest. UBS raised its price target from $1,140 to $1,310 on February 4, citing the strong backlog and structural labor shortages that create pricing power. Stifel bumped its target to $1,196, while the Wall Street consensus sits at $1,247 with six Buy ratings versus two Holds.

The Valuation Debate and What’s Next Here’s where it gets interesting. The stock trades at 42x forward earnings and carries a 2.06 PEG ratio, pricing in substantial growth. Yet insiders have been selling aggressively. CFO William George sold 9,649 shares totaling roughly $7.3 million on December 1, while CEO Brian Lane unloaded 7,158 shares worth $6.8 million on November 24. No insider buying has occurred in the past three months.

The rest of 2026 hinges on whether data center demand sustains these growth rates. Wall Street expects 35.2% revenue growth to continue, but any slowdown in AI infrastructure spending would pressure the premium valuation. Investors should watch the backlog closely when Q4 results drop.

Several infrastructure companies have reported outstanding backlog growth in recent weeks, with Vertiv (NYSE: VRT) reporting orders that grew 252% year-over-year earlier this week. Shares jumped more than 22% the next day in response.

Key Takeaways Ralph Lauren's Q3 adjusted gross margin rose 140 bps to 69.8% and operating margin rose 200 bps to 20.7%.Full-price sales, higher AUR and reduced discounting drove the margin expansion.Strong demand in Asia, and selective discounting in the U.S. and Europe boosted overall sales quality. Ralph Lauren Corporation’s (RL - Free Report) recent margin expansion underscores how brand elevation and disciplined execution are translating into tangible financial gains. In the third quarter of fiscal 2026, the company delivered a standout performance, exceeding expectations on both revenues and profitability despite a complex macro backdrop marked by tariffs and cost pressures. Central to this outcome was a decisive shift toward higher-quality sales, as full-price demand strengthened across regions, channels and product categories. Rather than chasing volume through promotions, Ralph Lauren leaned into its lifestyle brand equity, reinforcing pricing power and improving the overall mix of its business.

The margin results from the quarter clearly reflect this strategy at work. On a constant-currency basis, adjusted gross margin expanded 140 basis points (bps) to 69.8%, while adjusted operating margin increased 200 bps to 20.7%. Management attributed this expansion primarily to strong full-price selling, reduced discounting and favorable channel and product mix, which more than offset higher U.S. tariffs and labor costs. Notably, average unit retail (AUR) rose 18% year over year, far exceeding initial expectations and serving as a key lever behind the gross margin upside.

Full-price demand was broad-based and consistent across geographies. Asia led the way, with strong consumer appetite in China and Japan supporting higher realized pricing and fewer promotions. In North America and Europe, Ralph Lauren selectively pulled back on discounts, even in a promotional competitive environment, without sacrificing comparable-store sales growth. This discipline allowed the company to improve “quality of sales,” a recurring theme in management’s commentary, reinforcing the notion that margin expansion is being driven by structural brand strength rather than short-term cost tailwinds.

Looking ahead, the durability of this margin story hinges on whether full-price momentum can be sustained amid ongoing tariff pressures and a volatile consumer environment. Management remains confident, pointing to continued brand heat, strong new customer acquisition and data-driven pricing and promotion strategies. While margins are expected to face near-term pressure in the fiscal fourth quarter due to tariffs and marketing timing, Ralph Lauren’s fiscal third-quarter performance suggests that full-price demand is not just a cyclical benefit but a core driver of long-term profitability within its “Next Great Chapter: Drive” strategy.

RL’s Price Performance, Valuation & EstimatesRalph Lauren’s shares have gained 7.1% in the past three months compared with the industry’s 9.1% growth.

Image Source: Zacks Investment Research

From a valuation standpoint, RL trades at a forward price-to-earnings ratio of 20.80X compared with the industry’s average of 16.38X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for RL’s fiscal 2026 and fiscal 2027 earnings per share (EPS) indicates year-over-year growth of 30.5% and 9.9%, respectively. The company’s EPS estimate for fiscal 2026 and fiscal 2027 has been northbound in the past 30 days.

Image Source: Zacks Investment Research

Ralph Lauren currently carries a Zacks Rank #2 (Buy).

Other Key Picks in the Consumer Discretionary SpaceColumbia Sportswear Company (COLM - Free Report) , which is a marketer and distributor of outdoor and active lifestyle apparel, footwear, accessories and equipment, currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for COLM’s current financial-year sales is expected to rise 2.1% from the corresponding year-ago reported figure. COLM delivered a trailing four-quarter earnings surprise of 25.2%, on average.

Vince Holding Corp. (VNCE - Free Report) provides luxury apparel and accessories in the United States and internationally. At present, the company flaunts a Zacks Rank of 1.

The Zacks Consensus Estimate for VNCE’s current fiscal-year sales and earnings implies growth of 2.1% and 26.3%, respectively, from the year-ago figures. VNCE delivered a trailing four-quarter earnings surprise of 229.6%, on average.

Revolve Group, Inc. (RVLV - Free Report) , which is a marketer and seller of designer apparel, shoes and accessories, currently carries a Zacks Rank #2.

RVLV delivered a trailing four-quarter earnings surprise of 61.7%, on average. The Zacks Consensus Estimate for RVLV’s current financial-year EPS indicates growth of 8.7% from the year-ago number.

HENDERSON, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the opening of two new model homes at its newest gated community,  Incanta Lago, within the prestigious Lake Las Vegas master plan in Henderson, Nevada. Located at 427 Terra Alta in Henderson, Toll Brothers invites home shoppers to tour the exquisitely designed model homes and experience the community’s luxurious lifestyle firsthand.

Incanta Lago is a private retreat that offers refined lakeside living with single- and two-story home designs featuring modern open-concept floor plans, expansive outdoor living spaces, and an array of personalization options. Homes in this community range from 2,488 to 3,293 square feet and include 3 to 4 bedrooms, up to 4.5 baths, and 3-car garages. Pricing starts from the mid-$900,000s.

"We are thrilled to unveil two new, sophisticated, and beautifully crafted model homes at Incanta Lago, the Barona and Vento, both showcasing the exceptional design and exquisite detail for which Toll Brothers is known," said Janet Love, Division President of Toll Brothers in Las Vegas. "This community offers home shoppers a rare opportunity to embrace luxurious lakeside living while enjoying an active and vibrant lifestyle."

The prestigious Lake Las Vegas location provides residents with access to resort-style amenities, championship golf courses, water sports, and lakefront dining. Membership at the Lake Las Vegas Sports Club, picturesque trails, and boating activities further enhance the active and social lifestyle available at Incanta Lago.

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

For more information and to schedule a tour of the new model homes at Incanta Lago, call (855) 700-8655 or visit TollBrothersLasVegas.com.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5bfe745a-5956-48f1-b1d9-15d25c2e87e5

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

-

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 3, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ: RR) securities between January 27, 2026 and 12:00 PM EST on January 29, 2026, inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR RICHTECH INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?

On January 27, 2026, Richtech announced a “collaboration” with Microsoft’s AI Co-Innovation Labs to “jointly develop and deploy agentic artificial intelligence capabilities in real-world robotic systems.” On this news, Richtech’s stock prices increased by 44.6%.

On January 29, 2026, at 12:00 PM EST, Hunterbrook Media published an article stating that, according to Microsoft, the so-called collaboration with Richtech “was a ‘standard’ customer program with ‘no commercial element.’” Further, “[t]his comes after Richtech missed its 10-K deadline, hampering its ability to raise money through at-the-market offerings.”

On this news, Richtech’s stock price fell $1.06, or 20.9%, to close at $4.02 per share on January 29, 2026, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Richtech claimed that it had a collaborative and commercial relationship with Microsoft when it did not; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Richtech securities during the Class Period, you may move the Court no later than April 3, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

Key Takeaways WST reported Q4 adjusted EPS of $2.04, up 12.1%, beating estimates by 11.5%.Q4 revenues rose 7.5% to $805M, driven by Proprietary and Contract segments.WST guides 2026 revenues of $3.21B-$3.27B and EPS of $7.82-$8.20, above consensus. West Pharmaceutical Services, Inc. (WST - Free Report) delivered adjusted fourth-quarter 2025 earnings per share (EPS) of $2.04, which moved up 12.1% year over year. The figure topped the Zacks Consensus Estimate by 11.5%.

The adjustments include expenses related to the amortization of acquisition-related intangible assets, among others.

GAAP EPS for the quarter was $1.82, reflecting an improvement of 2.2% from the year-ago figure.

Full-year adjusted EPS was $7.29, up 8% from the comparable 2024 period.

WST’s Revenues in DetailWest Pharmaceutical registered revenues of $805 million in the fourth quarter, up 7.5% year over year. The figure surpassed the Zacks Consensus Estimate by 1.4%.

Organic net sales, which exclude the impact of acquisitions and/or divestitures, were up 3.3% year over year.

Robust performances by the Proprietary Products and Contract-Manufactured Products segments drove the top-line improvement.

Full-year 2025 revenues were $3.07 billion, reflecting a 6.3% increase from the comparable 2024 period. On an organic basis, revenues were up 4.3% year over year.

Shares of WST were up nearly 3.6% in today’s pre-market trading. The company’s shares have gained 2.6% in the past six months compared with the industry’s growth of 21.8% and the S&P 500 Index’s rise of 9.9%.

Image Source: Zacks Investment Research

West Pharmaceutical’s Segment DetailsWST operates under two segments — Proprietary Products and Contract-Manufactured Products.

In the quarter under review, Proprietary Products reported worldwide revenues of $661.8 million, up 7.8% year over year on a reported basis. Our estimate for the segment’s revenues was pinned at $645.3 million.

On an organic basis, revenues were up 3.6% year over year.

The segment’s high-value product (HVP) accounted for 48% of its net sales during the period. Sales of HVP components were up 20.3%, driven by strength in Westar and Envision products. HVP Delivery Devices, which represented 14% of total company net sales, decreased 16.9%. The decline was primarily due to the absence of a non-recurring fee of $25 million recorded in the year-ago quarter. Standard Products, 20% of total company net sales, increased 3%.

Revenues in the Contract-Manufactured Products segment totaled $143.2 million, up 6.2% year over year on a reported basis. This growth was driven by an increase in sales of self-injection devices for obesity and diabetes, partially offset by a decrease in sales of healthcare diagnostic devices. Our estimate for this segment’s fourth-quarter revenues was pegged at $147.4 million.

Organically, revenues were up 1.9% year over year.

WST’s Margin AnalysisIn the quarter under review, West Pharmaceutical’s gross profit increased 11.1% year over year to $303.9 million. The gross margin expanded 130 basis points (bps) to 37.8%. We had projected a 35.3% gross margin for the fourth quarter of 2025.

Selling, general and administrative expenses increased 25.4% year over year to $107 million. Research and development expenses increased 17.8% to $21.8 million.

Adjusted operating profit totaled $172 million, reflecting a 5.7% improvement from the year-ago quarter’s level. The adjusted operating margin contracted 30 bps to 21.4%. We had projected a 17.9% operating margin for the quarter.

West Pharmaceutical’s Financial PositionWST exited the fourth quarter with cash and cash equivalents of $791.3 million compared with $628.5 million as of September-end. Total debt at the end of 2025 was $202.8 million compared with $202.7 million as of September-end.

Cumulative net cash provided by continuing operating activities at the end of 2025 was $754.8 million compared with $653.4 million a year ago.

West Pharmaceutical has a consistent dividend-paying history, with a five-year annualized dividend growth rate of 5.39%.

WST’s Guidance for Q1 & 2026West Pharmaceutical has issued first-quarter guidance and updated its financial outlook for 2026.

WST expects its first-quarter sales to lie between $770 million and $790 million, implying organic growth of 4.6-7.4%. The company expects EPS to be in the range of $1.65-$1.70. The Zacks Consensus Estimate for first-quarter sales and EPS is pegged at $759.7 million and $1.64, respectively.

WST projects full-year revenues to be between $3.21 billion and $3.27 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Full-year revenues include a 2% benefit based on current foreign exchange rates. The Zacks Consensus Estimate is pegged at $3.24 billion.

For 2026, organic net sales are expected to grow 5-7% from the prior-year level.

For the full year, adjusted EPS is now anticipated to be in the range of $7.85-$8.20. The Zacks Consensus Estimate is pegged at $7.67.

Margin Expansion & HVP Momentum Set the Stage for 2026West Pharmaceutical exited the fourth quarter of 2025 with better-than-expected results. Solid top-line results, along with improvements in organic revenues, were impressive. Robust performance by the Proprietary Products segment was encouraging. Strength in HVP and robust growth in the Biologics and Pharma market units during the reported quarter were also promising. Gross margin expansion and improving organic revenue trends reinforce confidence in the company’s execution capabilities.

WST’s management attributed the strong finish to 2025 to the consistent execution of its growth strategy. The HVP Components business within the Proprietary Products segment supported double-digit growth in adjusted earnings per share. The company expects momentum to carry into 2026, positioning the year as an important period for focused execution and operational discipline aimed at sustaining growth and enhancing long-term value for patients, customers and shareholders.

Management’s 2026 sales outlook suggests steady demand fundamentals, favorable currency tailwinds and portfolio optimization initiatives, including the planned SmartDose divestiture.

West Pharmaceutical’s Zacks Rank & Other Stocks to ConsiderWST currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Merit Medical Systems (MMSI - Free Report) and Masimo Corporation (MASI - Free Report) .

Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 15.7%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Intuitive Surgical’s shares have gained 3.7% against the industry’s 3.6% decline in the past six months.

Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.3%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.1%.

Merit Medical stock has declined 4.1% against the industry’s 24.5% gain in the past six months.

Masimo, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17.1%. MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.4%.

Masimo’s shares have lost 10% compared with the industry’s 3.5% decline over the past six months.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call February 12, 2026 8:00 AM EST

Company Participants

John Sweeney - Vice President of Investor Relations
Eric Green - Non-Independent Chair of the Board, President & CEO
Robert McMahon - Senior VP & CFO

Conference Call Participants

Michael Ryskin - BofA Securities, Research Division
Daniel Markowitz - Evercore ISI Institutional Equities, Research Division
Justin Bowers - Deutsche Bank AG, Research Division
Paul Knight - KeyBanc Capital Markets Inc., Research Division
David Windley - Jefferies LLC, Research Division
Patrick Donnelly - Citigroup Inc., Research Division
Matthew Larew - William Blair & Company L.L.C., Research Division
Daniel Leonard - UBS Investment Bank, Research Division
Brendan Smith - TD Cowen, Research Division
Tom DeBourcy - Nephron Research LLC
Douglas Schenkel - Wolfe Research, LLC

Presentation

Operator

Good day, and thank you for standing by.

Welcome to the West Pharmaceutical Services' Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that today's conference is being recorded. I will now hand the conference over to your speaker host for today, John Sweeney, Vice President of Investor Relations. Please go ahead.

John Sweeney
Vice President of Investor Relations

Good morning, and welcome to West's Fourth Quarter and Full Year 2025 Earnings Conference Call, which is being webcast live. With me today on the call are West's CEO, Eric Green; and CFO, Bob McMahon. Earlier today, we issued our fourth quarter and full year financial results. A copy of the press release, along with today's slide presentation containing supplemental information for your reference has been posted in the Investors section of the company website located at investor.westpharma.com.

Later today, a replay of the webcast will also be available in the Investors section of our website. On the call, we will review our financial results and provide an update to our business and outlook for FY '26. Statements made by management on the

Check Point Software Technologies Ltd. (CHKP) Q4 2025 Earnings Call Transcript

Belden Inc. (BDC) Q4 2025 Earnings Call February 12, 2026 8:30 AM EST

Company Participants

Aaron Reddington - Vice President of Investor Relations
Ashish Chand - President, CEO & Director
Jeremy Parks - Senior VP of Finance & CFO

Conference Call Participants

Mark Delaney - Goldman Sachs Group, Inc., Research Division
William Stein - Truist Securities, Inc., Research Division
Steven Fox - Fox Advisors LLC
David Williams - The Benchmark Company, LLC, Research Division
Robert Jamieson - Vertical Research Partners, LLC
Christopher Dankert - Loop Capital Markets LLC, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to this morning's Belden reports fourth quarter 2025 results. Just a reminder, this call is being recorded.

[Operator Instructions]

I would now like to turn the call over to Aaron Reddington. Please go ahead, sir.

Aaron Reddington
Vice President of Investor Relations

Good morning, everyone, and thank you for joining us for Belden's Fourth Quarter and Full Year 2025 Earnings Conference Call. With me today are Belden's President and CEO, Ashish Chand; and Executive Vice President and CFO, Jeremy Parks. Ashish will provide a strategic overview of our business, and then Jeremy will provide a detailed review of our financial and operating results, followed by Q&A.

We issued our earnings release earlier this morning and have prepared a slide presentation that we will reference on this call. The press release, presentation and transcript of these prepared remarks are currently available online at investor.belden.com.

Turning to Slide 2. I'd like to remind everyone that today's call will include forward-looking statements, which are subject to risks and uncertainties as detailed in our press release and most recent Form 10-K. We will also reference certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures can be found in the appendix to our presentation and on our website.

, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against uniQure N.V. (NASDAQ: QURE) ("uniQure" or the "Company") on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025, inclusive (the "Class Period").  This action, captioned Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was filed in the United States District Court for the Southern District of New York.

Important Deadline Reminder:  Investors who purchased or otherwise acquired uniQure ordinary shares during the Class Period may, no later than April 13, 2026, move the Court to serve as lead plaintiff for the class. 

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
If you experienced losses in connection with uniQure, contact Kessler Topaz Meltzer & Check, LLP at:

https://www.ktmc.com/qure-uniqure-nv-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=qure&mktm=PR 

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. 

UNIQURE N.V. CLASS ACTION LAWSUIT COMPLAINT ALLEGEGATIONS

uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease ("HD").  uniQure is incorporated in The Netherlands with its principal executive offices in Amsterdam, The Netherlands.

The Company's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD, a usually fatal, inherited genetic disorder that causes nerve cells in the brain to break down, leading to problems with movement and thinking, as well as psychiatric issues.  There is no existing cure or approved means for slowing the progression of the disease.  Some drugs can address certain HD symptoms, but do not halt its progression to a usually fatal outcome.  AMT-130 is one of a very few drugs in testing intended to slow the progression of HD.  In March 2022, uniQure completed patient enrollment for two, ongoing multi-center, dose-escalating Phase I/II clinical trials for AMT-130 called the Pivotal Phase I/II Study of AMT-130 in patients with HD (the "Pivotal Study"). 

According to the Defendants, the U.S. Food and Drug Administration ("FDA") previously agreed that uniQure's Pivotal Study would not include any placebo comparator, but instead, the Pivotal Study results could be compared to an external historical data set, known as Enroll-HD or ENROLL-HD, and the analysis derived from such comparison potentially could serve as the basis for uniQure's Biologics License Application ("BLA") submission to the FDA for approval to use AMT-130 to treat patients with HD.

Indeed, Defendant Matthew Kapusta, the Company's Chief Executive Officer, assured investors of the Company's alignment with the FDA during calls with investors on June 2, 2025, and July 29, 2025. 

The Class Period begins on September 24, 2025, when the Company announced topline results of the Pivotal Study.   Notably, the Company emphasized that AMT-130 saw a "mean reduction from baseline in cerebrospinal neurofilament light protein" ("CSF NfL")—which uniQure asserted was "a well-characterized, supportive biomarker of neurodegeneration."  Accordingly, uniQure explained that "[e]levation in CSF NfL has been shown to be strongly associated with greater clinical severity of [HD]."  Thus, based on the totality of the results and as compared to data from ENROLL-HD, investors were led to believe that AMT-130 was effective in slowing the neurodegeneration in patients with HD and that uniQure would file for accelerated approval of a BLA for AMT-130 in the near-term.  During the related investor conference held that same day, Defendant Kapusta touted the study results and asserted that "we believe these findings provide compelling and clinically meaningful evidence of AMT-130 disease modifying potential." 

Additionally, Defendant Walid Abi-Saab, the Company's Chief Medical Officer, reminded investors that uniQure previously discussed the trial design with the FDA and that the FDA agreed that "cUHDRS could serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval."  Moreover, he stated that "[t]he FDA also agreed that ENROLL-HD . . . may be acceptable as the external control dataset for the primary analysis, with each dose matched the corresponding controls based on their baseline characteristics."   Thus, investors were led to believe that there was a high likelihood that AMT-130 would receive accelerated approval from the FDA after the Company's planned BLA submission in the first quarter of 2026.  The market acted accordingly and, in response to Defendants' statements, the price of the Company's ordinary shares jumped from a close of $13.66 per share on September 23, 2025, to close at $47.50 per share on September 24, 2025, a nearly 250% increase.  By October 29, 2025, uniQure ordinary shares were trading above $70.00 per share.

Capitalizing on the substantial increase in the value of uniQure ordinary shares, the Company publicly offered more than 5.7 million uniQure ordinary shares, and more than 500,000 pre-funded warrants to purchase ordinary shares, over the next several days after the release of the Pivotal Study results (the "September 2025 Offering").  Despite the fact that AMT-130's future remained uncertain pending uniQure's discussion of the Pivotal Study results with the FDA, in the prospectus supplement to the September 2025 Offering, uniQure explained that it was engaging in the September 2025 Offering in order to "fund our commercialization readiness activities" and "the potential commercial launch of AMT-130 and related commercialization activities."  Through the September 2025 Offering, uniQure generated approximately $345 million in proceeds (before expenses). 

Investors learned the truth about the Company's prospects and the BLA timeline for AMT-130 on November 3, 2025, when uniQure revealed that "the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission."  Although the Company "plan[ned] to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130," uniQure admitted that "the timing of the BLA submission for AMT-130 is now unclear."  On this news, the price of uniQure ordinary shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025. 

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company's business and operations.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

THE LEAD PLAINTIFF PROCESS FOR UNIQURE INVESTORS:

uniQure investors may, no later than April 13, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages uniQure investors to contact the firm directly for more information about the lawsuit.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar.  The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. 

CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]         

May be considered attorney advertising in certain jurisdictions.  Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

Key Takeaways TROW's January AUM reached $1.80T, up 1.2% from December 2025.Multi-asset and target-date portfolios drove sequential growth in TROW's AUM.Equity AUM remained flat while fixed income and alternatives rose modestly. T. Rowe Price Group, Inc. (TROW - Free Report) has announced preliminary assets under management of $1.80 trillion as of Jan. 31, 2026, reflecting a 1.2% increase from the prior month. The company experienced net outflows of $5.2 billion during the month, which were partially offset by favorable market performance.

At the end of January, T. Rowe Price’s equity products totaled $879 billion, unchanged from December 2025. Fixed income (including money market) rose marginally to $213 billion, while multi-asset products increased nearly 3% to $646 billion, reflecting strong client demand. Alternative products also reached $59 billion, up 1.7% sequentially.

Meanwhile, the company’s target-date retirement portfolios totaled $580 billion, rising 3.4% from the prior month, demonstrating the continued strength of the company’s retirement-focused franchise.

T. Rowe Price benefits from a well-diversified AUM mix across asset classes, client segments and geographies, providing stability to its asset base. Over the five years (2020-2025), the company’s AUM registered a compound annual growth rate (CAGR) of 3.8%, supported by market appreciation and sustained demand for multi-asset and fixed-income solutions.

TROW’s long-term performance has also remained resilient. Over the past five years ending Dec. 31, 2025, 46% of the company’s U.S. mutual funds’ AUM outperformed the Morningstar median, while 43% exceeded the passive peer median. Along with strong fund performance, investment advisory clients outside the United States represented 8.8% of total AUM, which underpins its geographic diversification.

Hence, supported by a strong brand, consistent investment track record and healthy business volumes, T. Rowe Price is well-positioned to sustain AUM growth in the upcoming period.

TROW’s Peers Showing Steady AUM ExpansionT. Rowe Price’s peers, including Franklin Resources, Inc. (BEN - Free Report) and Invesco Ltd. (IVZ - Free Report) , have also recorded steady growth in their AUM.

Franklin reported a preliminary AUM of $1.71 trillion as of Jan. 31, 2026, up 1.3% sequentially. Growth was driven by market appreciation and long-term net inflows of $1.5 billion, partially offset by net outflows at Western Asset Management. Over the last five fiscal years ending 2025, Franklin’s AUM recorded a CAGR of 3.1%, supported by strategic acquisitions and partnerships that have strengthened its alternatives, retirement and ETF offerings.

Invesco also recorded steady AUM growth. Despite a decline in 2022, Invesco’s five-year CAGR ended 2025 at 10%. The 2019 OppenheimerFunds acquisition boosted its AUM, while private market partnerships with LGT Capital Partners and Barings, and December 2025 QQQ Trust conversion into an open-end ETF, have supported over $400 billion of AUM and revenue growth.

T. Rowe Price’s Zacks Rank & Price PerformanceOver the past six months, TROW shares have lost 14.7% compared with the industry’s 14.9% decline.

Image Source: Zacks Investment Research

Currently, T. Rowe Price carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CoreWeave, Inc. (NASDAQ: CRWV) between March 28, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important March 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased CoreWeave securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the CoreWeave class action, go to https://rosenlegal.com/submit-form/?case_id=50571 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants had overstated CoreWeave's ability to meet customer demand for its service; (2) defendants materially understated the scope and severity of the risk that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (3) the foregoing was reasonably likely to have a material negative impact on CoreWeave's revenue; (4) as a result, CoreWeave's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the CoreWeave class action, go to https://rosenlegal.com/submit-form/?case_id=50571 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283726

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Advance Auto Parts (AAP - Free Report) . This company, which is in the Zacks Automotive - Retail and Wholesale - Parts industry, shows potential for another earnings beat.

This auto parts retailer has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 20.64%.

For the last reported quarter, Advance Auto Parts came out with earnings of $0.92 per share versus the Zacks Consensus Estimate of $0.74 per share, representing a surprise of 24.32%. For the previous quarter, the company was expected to post earnings of $0.59 per share and it actually produced earnings of $0.69 per share, delivering a surprise of 16.95%.

Price and EPS Surprise

With this earnings history in mind, recent estimates have been moving higher for Advance Auto Parts. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Advance Auto Parts has an Earnings ESP of +1.22% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on February 13, 2026.

With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Leidos (LDOS - Free Report) , which belongs to the Zacks Computers - IT Services industry.

This security and engineering company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 19.46%.

For the most recent quarter, Leidos was expected to post earnings of $2.61 per share, but it reported $3.05 per share instead, representing a surprise of 16.86%. For the previous quarter, the consensus estimate was $2.63 per share, while it actually produced $3.21 per share, a surprise of 22.05%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Leidos lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Leidos has an Earnings ESP of +0.20% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on February 17, 2026.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

PG delivers modest sales growth in Q2 but faces margin pressure, tariff headwinds and soft EPS outlook, as premium valuation tests upside potential.

Key Takeaways OTLY shares rose 10.7% after Q4 revenues beat estimates and the gross margin expanded 579 bps y/y.OTLY's Q4 sales up 9.1%, led by 23.3% growth in Europe & International, and volume gains in Barista products.OTLY expects 2026 revenue growth of 3-5% and adjusted EBITDA of $25M-$35M despite headwinds in North America. Oatly Group AB (OTLY - Free Report) posted fourth-quarter 2025 results, wherein both the top and bottom lines increased year over year. The top line surpassed the Zacks Consensus Estimate, while the bottom line missed the same.

Oatly’s fourth-quarter results indicate that the company is moving into a new phase of its turnaround, with early signs that the actions taken over the past several years are translating into more consistent and sustainable performance.

While challenges remain in certain markets, management highlighted improving momentum where the refreshed growth playbook has been fully implemented, supported by supply-chain efficiencies, tighter cost control and more focused investment behind the core beverage portfolio. Reflecting this shift in sentiment, OLTY shares gained 10.7% yesterday, suggesting growing investor confidence in the company’s trajectory.

More on Oatly’s Q4 ResultsThis oat drink company posted a quarterly loss of 61 cents per share in the quarter under review. The reported figure was wider than the Zacks Consensus Estimate of a loss of 54 cents. However, the bottom line improved significantly from the loss of $3.05 incurred in the year-earlier quarter.

Total revenues of $233.8 million surpassed the Zacks Consensus Estimate of $217 million and increased 9.1% year over year on a reported basis and 4.3% on a constant-currency basis. Constant-currency growth reflected another quarter of steady performance in Europe & International, partly offset by a decline in North America due to reduced sales to a large foodservice customer, as well as a slight decrease in Greater China.

Sold volume rose 2.9% to 157.6 million liters from 153.2 million liters in the fourth quarter of 2024. Produced finished goods volume increased to 161.5 million liters from 145.3 million liters in the prior-year quarter.

OTLY’s Margin & Cost DetailsGross profit improved 31.1% year over year to $80.8 million and the gross margin expanded 579 basis points year over year to 34.5%. The margin improvement was driven by supply-chain efficiencies in Europe & International, and favorable product and channel mix in North America and Greater China.

Research and development expenses increased 35.5% year over year to $5.1 million, primarily reflecting costs associated with product launches and foreign currency exchange headwinds. Selling, general and administrative expenses rose 2.3% to $83.9 million. The increase was mainly due to foreign currency exchange headwinds and higher customer distribution costs tied to increased sold volumes, partially offset by ongoing efforts to lower overhead.

Adjusted EBITDA for the fourth quarter of 2025 was $11 million against a loss of $6.1 million in the prior-year period. The year-over-year improvement was primarily driven by higher gross profit.

OTLY’s Q4 Revenue Insights by RegionsEurope & International revenues increased 23.3% year over year to $133.7 million in the fourth quarter of 2025, which beat the Zacks Consensus Estimate of $123.6 million. Excluding a $9.9-million foreign currency exchange tailwind, revenues were $123.9 million, representing growth of 14.2%. The increase was primarily driven by volume growth of 13.9%, led mainly by Barista products. Approximately 79% of Europe & International revenues came from the retail channel in the fourth quarter compared with 81% in the prior year. The sold finished goods volume for the three months ended Dec. 31, 2025, and 2024 totaled 89.3 million liters and 78.3 million liters, respectively.

Adjusted EBITDA increased by $9.9 million to $26.5 million. The improvement was primarily driven by higher gross profit resulting from increased revenues and continued supply-chain productivity.

North America revenues decreased 8.8% year over year to $64.4 million, which lagged the Zacks Consensus Estimate of $65.1 million. The sold finished goods volume decreased 12.6% to 35.8 million liters due to reduced sales to the segment’s largest foodservice customer. Retail represented approximately 61% of North America revenues in the quarter compared with 48% in the prior-year period.

Adjusted EBITDA increased by $3.1 million year over year to $4.4 million. The improvement was driven by higher gross profit, largely reflecting favorable channel and product mix, and improved supply-chain performance, which more than offset lower fixed cost absorption associated with reduced volumes.

OTLY Stock Past 3-Month Performance

Image Source: Zacks Investment Research

Greater China revenues increased 1.1% year over year to $35.7 million, which surpassed the Zacks Consensus Estimate of $28.6 million. Excluding a $0.4-million foreign currency exchange tailwind, revenues were $35.2 million, representing a slight decrease of 0.1%.

The modest decline on a constant-currency basis was primarily due to reduced foodservice sales, partially offset by growth in the retail channel. Foodservice accounted for approximately 66% of segment revenues compared with 76% in the prior-year period. The sold finished goods volume declined to 32.5 million liters from 33.8 million liters.

Adjusted EBITDA increased by $0.5 million to $1.1 million. The improvement was driven by higher gross profit, reflecting a favorable channel and product mix.

Oatly’s Financial Health SnapshotThe company ended the quarter with cash and cash equivalents of $64.3 million, and total outstanding debt of $523 million, consisting of Nordic Bonds, Convertible Notes and liabilities to credit institutions. Net cash used in operating activities was $23.7 million for the 12 months of 2025.

Capital expenditure totaled $15.3 million for the 12 months ended Dec. 31, 2025, compared with $41.2 million in the prior year. The decrease reflects the company’s continued investment discipline, as well as certain projects originally expected to be completed in 2025 that are now anticipated to be completed in 2026.

The free cash flow was an outflow of $39 million for the 12 months ended Dec. 31, 2025, compared with an outflow of $155.6 million in the prior-year period. The improvement was driven by lower cash used in operating activities and reduced capital expenditure.

Other DevelopmentsThe company continues to conduct a strategic review of its Greater China business. While there is no definitive timetable for completion, the company currently expects the review to conclude by 2026.

Sneak Peek Into OTLY’s 2026 OutlookThe company’s outlook continues to include the expected results of the Greater China segment. Based on its assessment of the current operating environment and the actions underway, the company is providing the following outlook for 2026.

Constant-currency revenue growth is expected to be 3-5%, including an anticipated headwind of 200 basis points related to a large foodservice customer in the North America segment. Based on recent foreign exchange rates, foreign currency is expected to provide a full-year revenue growth tailwind of 100-200 basis points.

Adjusted EBITDA is expected to be $25-$35 million. Capital expenditure is expected between $20 million and $30 million.

Shares of this Zacks Rank #3 (Hold) company have lost 3.9% in the past three months as compared with the industry’s decline of 3%.

Key PicksWe have highlighted three better-ranked stocks, namely Hershey Company (HSY - Free Report) , The Simply Good Foods Company (SMPL - Free Report) and Medifast (MED - Free Report) .

Hershey manufactures pantry items like baking ingredients, toppings and beverages; gum and mint refreshment products; and snack bites and mixes, as well as spreads. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Hershey’s current financial-year earnings and revenues implies growth of 27.1% and 4.4%, respectively, from the year-ago actuals. HSY delivered a trailing four-quarter average earnings surprise of 17.2%.

Simply Good Foods’ product portfolio consists primarily of nutrition bars, ready-to-drink shakes, snacks and confectionery products. It currently has a Zacks Rank of 2 (Buy).

SMPL delivered a trailing four-quarter earnings surprise of 5.5%, on average. The consensus estimate for Simply Good Foods’ current fiscal-year sales and earnings indicates a decline of 0.3% and growth of 1.6%, respectively, from the year-ago period’s reported figures.

Medifast is a leading manufacturer and distributor of clinically-proven healthy living products and programs. It has a Zacks Rank of 2 at present.

The Zacks Consensus Estimate for Medifast’s current financial-year earnings and revenues implies declines of 156.5% and 36.7%, respectively, from the year-ago actuals. MED delivered a negative trailing four-quarter average earnings surprise of 640%.

Marimekko Oyj (MKKOF) Q4 2025 Earnings Call February 12, 2026 7:00 AM EST

Company Participants

Anna Tuominen - Communications Director
Tiina Alahuhta-Kasko - CEO & President
Elina Anckar - Chief Financial Officer

Presentation

Anna Tuominen
Communications Director

Good afternoon, ladies and gentlemen. My name is Anna Tuominen. I'm the IRO of Marimekko. Thank you for joining us today. We have the opportunity to hear our President and CEO, Tiina Alahuhta-Kasko, in a few minutes to go through Marimekko's Q4 and full year results from 2025. And after that, we have reserved some time for Q&A with Tiina and our CFO, Elina Anckar, answering your questions. You can type in your questions using the chat function already during the presentation and then we'll start going through them after we first heard Tiina's wise words.

Tiina, please go ahead.

Tiina Alahuhta-Kasko
CEO & President

Thank you so much, Anna, and good afternoon, everyone. It's my pleasure to share with you a few words about Marimekko's results in 2025. So let's get started with the fourth quarter of the year. As it pertains to our business development in the last quarter of the year, of course, the market situation continued to be challenging. But despite of that, our net sales grew from the comparison period's record level, fueled by our international sales and our operating profit margin was at a good level. Altogether, our net sales in the fourth quarter grew by 1% and totaled EUR 54.7 million.

Our net sales were driven especially by increased retail and wholesale sales in the Asia Pacific region in spite of the globally uncertain market situation and the weak consumer confidence. In total, our international sales increased by 5%. Net sales in our home market in Finland were down by just 1% as retail sales declined in the environment that in Finland

Baxter International Inc. (BAX) Q4 2025 Earnings Call February 12, 2026 8:30 AM EST

Company Participants

Kevin Moran - Vice President & Head of Investor Relations
Andrew Hider - CEO, President, Interim Group President of Medical Products & Therapies and Director
Joel Grade - Executive VP & CFO

Conference Call Participants

David Roman - Goldman Sachs Group, Inc., Research Division
Robert Marcus - JPMorgan Chase & Co, Research Division
Vijay Kumar - Evercore ISI Institutional Equities, Research Division
Larry Biegelsen - Wells Fargo Securities, LLC, Research Division
Travis Steed - BofA Securities, Research Division
Danielle Antalffy - UBS Investment Bank, Research Division
Joanne Wuensch - Citigroup Inc., Research Division

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to the Baxter International's Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

I would now like to turn the call over to Mr. Kevin Moran, Vice President, Investor Relations at Baxter International. Mr. Moran, you may begin.

Kevin Moran
Vice President & Head of Investor Relations

Good morning, and welcome. Today, we will discuss Baxter's fourth quarter results, along with our financial outlook for the full year 2026. This morning, a press release was issued with our preliminary earnings results and updated outlook. The press release and investor presentation are available on the Investors section of the Baxter website.

Joining me today are Andrew Hider, President and Chief Executive Officer; and Joel Grade, Executive Vice President and Chief Financial Officer.

During the call, we will be making forward-looking statements, including comments regarding our financial outlook for the full year 2026 and anticipated timing and impact of our deleveraging efforts. The amount and timing of charges related to recent

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Brookfield Corporation (BN:CA) Q4 2025 Earnings Call February 12, 2026 10:00 AM EST

Company Participants

Katie Battaglia
J. Flatt - Chief Executive Officer
Nicholas Goodman - President & CFO
Sachin Shah - Chief Executive Officer of Wealth Solutions

Conference Call Participants

Kenneth Worthington - JPMorgan Chase & Co, Research Division
Bart Dziarski - RBC Capital Markets, Research Division
Alexander Blostein - Goldman Sachs Group, Inc., Research Division
Michael Cyprys - Morgan Stanley, Research Division
Mario Saric - Scotiabank Global Banking and Markets, Research Division
Jaeme Gloyn - National Bank Financial, Inc., Research Division
Cherilyn Radbourne - TD Cowen, Research Division
Sohrab Movahedi - BMO Capital Markets Equity Research

Presentation

Operator

Good day, and welcome to the Brookfield Corporation Fourth Quarter 2025 Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Ms. Katie Battaglia, Vice President, Investor Relations. Please go ahead.

Katie Battaglia

Thank you, operator, and good morning. Welcome to Brookfield Corporation's Fourth Quarter and Full Year 2025 Conference Call. On the call today are Bruce Flatt, our Chief Executive Officer; Nick Goodman, President of Brookfield Corporation; and Sachin Shah, Chief Executive Officer of our Wealth Solutions business. Bruce will start off by giving a business update, followed by Nick, who will discuss our financial and operating results for the year. And finally, Sachin will provide an update on our Wealth Solutions business.

After our formal comments, we'll turn the call over to the operator and take analyst questions. In order to accommodate all those who want to ask questions, we request that you refrain from asking more than 2 questions.

I would like to remind you that in today's comments, including in responding to questions and in discussing new initiatives in our financial and operating performance, we may make forward-looking

Q4: 2026-02-12 Earnings SummaryEPS of $0.95 beats by $0.07

 |

Revenue of

$15.56B

(4.81% Y/Y)

beats by $98.83M

Anheuser-Busch InBev SA/NV (BUD) Q4 2025 Earnings Call February 12, 2026 9:00 AM EST

Company Participants

Michel Doukeris - Chief Executive Officer
Fernando Tennenbaum - Chief Financial Officer

Conference Call Participants

Edward Mundy - Jefferies LLC, Research Division
Robert Ottenstein - Evercore ISI Institutional Equities, Research Division
Sanjeet Aujla - UBS Investment Bank, Research Division
Trevor Stirling - Bernstein Institutional Services LLC, Research Division
Andrea Pistacchi - BofA Securities, Research Division
Mitchell Collett - Deutsche Bank AG, Research Division
Gen Cross - BNP Paribas, Research Division
Sarah Simon - Morgan Stanley, Research Division

Presentation

Operator

Welcome to AB InBev's Full Year 2025 Earnings Conference Call and Webcast. Hosting the call today from AB InBev are Mr. Michel Doukeris, Chief Executive Officer; and Mr. Fernando Tennenbaum, Chief Financial Officer. [Operator Instructions] Today's webcast will be available for on-demand playback later today.

[Operator Instructions] Some of the information provided during the conference call may contain statements of future expectations and other forward-looking statements. These expectations are based on management's current views and assumptions and involve known and unknown risks and uncertainties.

It is possible that AB InBev's actual results and financial condition may differ, possibly materially from the anticipated results and financial condition indicated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect AB InBev's future results, see risk factors in the company's latest annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2025.

AB InBev assumes no obligation to update or revise any forward-looking information provided during the conference call and shall not be liable for any action taken in reliance upon such information. It is now my pleasure to turn the floor over to Mr. Michel Doukeris. Sir, you may begin.

Michel Doukeris
Chief Executive Officer

Thank you, and welcome, everyone, to our full

Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials.

“We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said.

Currently, Wegovy is available in both injectable and oral forms.

The move follows rival Eli Lilly, which began offering vials of the two lowest doses of its weight-loss drug Zepbound in 2024. Last year, Lilly reduced prices for Zepbound vials and expanded the range of doses available online.

Zepbound overtook Wegovy in US prescriptions during 2025, marking a challenging period for Novo Nordisk. The company’s plan to introduce vials is seen as part of its effort to regain market share in the competitive obesity-drug sector.

Shares of Novo Nordisk traded down 0.9% on Thursday at about $48, down about 5% so far this year.

A notable shift has been unfolding beneath the surface of the market in recent months, one that many investors may have overlooked. While the major indexes have remained flat or pushed modestly higher, leadership has quietly rotated. Outside of a narrow group of AI-linked names, much of the AI ecosystem, along with the Magnificent 7 have largely paused after extended runs.

This type of consolidation among market leaders is both typical and healthy. More importantly, it has coincided with a broadening of the rally, as the remaining 493 members of the S&P 500 increasingly participate in the advance. Historically, expanding market breadth has been associated with more durable bull markets, suggesting the current backdrop remains supportive for stock market investors.

Against this improving landscape, a number of underfollowed stocks are beginning to stand out. Companies with strong Zacks Ranks, reasonable valuations, and constructive price momentum are quietly moving higher without attracting widespread attention. Flexsteel Industries ((FLXS - Free Report) ), Allegiant Air ((ALGT - Free Report) ), and Hershey ((HSY - Free Report) ) fit that description and deserve a closer look from investors seeking opportunities beyond the market’s most crowded trades.

Image Source: Zacks Investment Research

Flexsteel Industries: Stock Forming Compelling Technical PatternFlexsteel Industries is a well-established manufacturer and importer of residential furniture, known for its durable seating products and broad distribution network spanning retail partners, e-commerce channels, and direct sales. While furniture demand can be cyclical and closely tied to housing and consumer spending trends, the company has spent the past several years streamlining operations, while the housing industry has quietly shown evidence of a rebound.

After a difficult stretch for the broader home furnishings space, the industry is off to a strong start in 2026, materially outperforming the market and currently ranking in the top 18% of the Zacks Industry Rank (43 out of 243 groups). Flexsteel itself carries a Zacks Rank #1 (Strong Buy), supported by meaningful upward revisions to earnings expectations. Estimates have climbed 15.5% for the current year and 11.5% for next year over just the past 30 days, a signal that analysts are growing increasingly confident in the company’s outlook.

Valuation remains reasonable. Shares trade at approximately 13.6x forward earnings, roughly in line with the company’s long-term average, which leaves room for potential multiple expansion if the industry recovery continues and execution remains solid.

Technically, the stock is exhibiting constructive behavior. Following a substantial earnings beat that triggered a sharp gap higher, shares have consolidated into what appears to be a high-and-tight flag pattern. This formation is often associated with continuation moves and suggests the potential for further upside should the stock break decisively above its recent range.

Image Source: TradingView

Allegiant: Shares Climb Following EarningsAllegiant Air is an ultra-low-cost carrier focused on connecting underserved cities to popular leisure destinations. The airline has carved out a defensible niche within the travel industry by emphasizing point-to-point routes, disciplined capacity growth, and ancillary revenue streams that help support margins even in a competitive pricing environment.

The airline industry itself has started 2026 on solid footing, ranking in the top 12% of the Zacks Industry Rank (28 out of 243 groups). Allegiant has been a clear beneficiary of this strength, with analysts raising earnings estimates by 21.3% for the current year and 10.5% for next year. These upward revisions support the company’s Zacks Rank #1 (Strong Buy) rating and reinforce improving confidence in its near-term trajectory.

Despite the stronger outlook, valuation remains attractive. Shares trade at roughly 13.8x forward earnings, while EPS is projected to expand at an impressive 51.3% annual rate over the next three to five years. That combination results in a PEG ratio of just 0.27, signaling that the stock may still be undervalued relative to its growth profile.

From a technical perspective, Allegiant is displaying a setup similar to other emerging leaders. After delivering a major earnings beat that sparked a sharp gap higher, the stock has consolidated into what appears to be a high-and-tight flag pattern, a formation often associated with institutional accumulation and potential continuation higher if the breakout confirms.

Image Source: TradingView

Hershey: Stock Rebounding from LowsThe Hershey Company remains one of the most entrenched consumer franchises in the United States, with a dominant position in confectionery and a portfolio of iconic brands that command pricing power and shelf space. Despite that strength, the stock experienced a sharp correction between 2023 and last year as investors rotated away from defensive names and grappled with margin pressures tied to input costs.

That backdrop is beginning to shift. Shares have rebounded from their lows and are gaining momentum as capital rotates toward diversification beyond the market’s crowded themes. In addition, Hershey recently delivered a strong earnings beat, prompting meaningful upward revisions to profit forecasts and earning the company a Zacks Rank #1 (Strong Buy).

Earnings estimates have climbed across multiple timeframes, with projections rising 17.4% for this year and 16.4% for next year. Those increases have occurred consistently over the past 60 days, 30 days, and again in the last week, signaling strengthening analyst conviction.

Technically, the setup mirrors the constructive patterns seen in other emerging leaders. Following its earnings-driven gap higher, Hershey has consolidated into what appears to be a high-and-tight flag formation.

Image Source: TradingView

Should Investors Buy Shares in HSY, ALGT and FLXS?A common theme connects these three stocks: each is emerging from a prolonged period of underperformance just as market leadership begins to broaden. While AI and mega-cap technology names captured the bulk of investor attention over the past year, many fundamentally sound businesses were quietly left behind. That dynamic now appears to be reversing.

With a resilient economic backdrop and improving earnings outlooks, investors are increasingly rotating toward durable companies with reasonable valuations and strengthening price momentum. Flexsteel, Allegiant, and Hershey may lack the headline appeal of tech, but their entrenched market positions and rising analyst conviction suggest they are worth serious consideration. For investors seeking opportunities beyond the market’s most crowded trades, these underfollowed names could offer attractive upside as the rally continues to widen.

Key Takeaways WFC shares have climbed 14.2% in six months, outpacing the industry's rise of 11.3%.WFC expects 2026 NII of $50B, aided by balance-sheet growth and loan mix changes.WFC cut headcount 5.9% in 2025 and refurbished 700 branches to improve efficiency. Shares of Wells Fargo & Company (WFC - Free Report) have gained 14.2% in the past six months compared with the industry’s rise of 11.3%. Its peers, Citigroup (C - Free Report) and Bank of America (BAC - Free Report) have risen 24% and 14%, respectively, over the same time frame.

Price Performance

Image Source: Zacks Investment Research

Given WFC’s impressive rally, investors might wonder if the opportunity to add this stock to their portfolio has passed. However, we believe that Wells Fargo has much going in its favor, and this rally is far from over.

Let us find out what is driving WFC’s performance and whether this is the right time to buy the stock.

Asset Cap Removal to Support WFC’s GrowthWells Fargo reached a milestone in June 2025 when the Federal Reserve lifted the asset cap imposed in 2018 following the bank’s fake account scandal. The removal eliminates a long-standing constraint on balance-sheet expansion, allowing the company to grow deposits, increase loan balances and expand securities holdings, thereby unlocking its full operating potential. At the UBS Financial Services Conference held on Feb. 10, WFC’s chief financial officer, Mike Santomassimo, stated that the company expects loan growth to pick up in 2026, with credit cards and auto lending leading the way. 

The regulatory relief also provides WFC with greater flexibility to scale fee-based businesses, including payment services, asset management and mortgage origination, supporting revenue diversification and long-term top-line growth. In sync with this, WFC is preparing to enter the options clearing business, reflecting rising demand from clients as options trading activity increases across markets.

With greater strategic flexibility and improved earnings visibility, management raised the company’s medium-term return on tangible common equity (ROTCE) target to 17-18% from the earlier 15%, indicating stronger profitability prospects over the next few years.

Fed Rate Cuts to Support WFC’s NIIOver the past few years, Wells Fargo’s net interest income (NII) has shown steady improvement, posting a four-year compounded annual growth rate (CAGR) of 7.5% ended 2025. 

The Federal Reserve lowered rates three times last year, to 3.5-3.75%, following a 100-basis-point (bp) cut in 2024. With lower rates, funding costs gradually stabilize, supporting increased borrowing, which means more loan volumes. Thus, WFC is expected to witness decent growth in NII in the quarters ahead, supported by lower funding costs, increased loan volumes and repricing of maturing assets into higher yields. 

Wells Fargo expects 2026 NII to reach $50 billion, driven by growth in the balance sheet and changes in loan and deposit mix, as well as continued fixed asset repricing.

2026 NII Outlook

Image Source: Wells Fargo & Company

WFC’s Branch Optimization & Expense Management to Aid GrowthWFC’s prudent expense management initiatives have been supporting its financials. The company has been actively engaged in cost-cutting measures, including streamlining organizational structure and headcount reductions. The company also keeps investing in and optimizing its branch network to reduce costs.

By the end of 2025, branches declined 2.1% year over year. Although Wells Fargo has reduced its overall footprint over the past decade, it has invested in branch renovations and new locations as part of a broader growth strategy. The ongoing upgrades aim to foster a more growth-oriented culture.
In 2025, the company refurbished approximately 700 branches, with more than half of its branch network now upgraded and the remaining branches expected to be completed over the next few years.  WFC’s headcount was reduced by 5.9% year over year by the end of 2025. 

The company is also advancing its operational transformation through a phased artificial intelligence (AI) rollout, aimed at improving productivity, streamlining workflows and enhancing customer service. In August 2025, the company expanded its strategic partnership with Google Cloud to deploy generative and agentic AI tools at scale. The bank also plans to introduce AI gradually over the next year and continue expanding its use beyond 2026. Management characterized the transition as a “positive reality,” suggesting that AI-enabled efficiencies will support long-term operational improvements. WFC grew mobile active customers by 1.4 million in 2025, up 4% from a year ago.

Though the company’s expenses for 2026 are projected to increase to $55.7 billion from $54.8 billion in 2025, its continued investments in digital infrastructure and process automation are expected to generate sustained expense savings and enhance overall profitability in the long term.

2026 Expense Outlook

Image Source: Wells Fargo & Company

WFC’s Multi-Year Simplification Plan to Enhance ReturnsWells Fargo has been pursuing a strategic exit from various non-core and lower-return businesses to streamline its focus on consumer banking, commercial lending and high-return areas. This effort, led by CEO Charlie Scharf since 2019, aims to cut costs significantly (targeting up to $10 billion annually) and reallocate capital to core franchises.

In sync with this, in January 2026, WFC sold its rail lease portfolio to a joint venture of GATX and Brookfield. In March 2025, the bank completed the sale of its non-agency third-party commercial mortgage servicing business to Trimont, backed by Varde Partners, reducing exposure to operationally complex commercial real estate servicing activities.

In 2023, WFC sold approximately $2 billion of private equity fund investments in Norwest Equity Partners and Norwest Mezzanine Partners to institutional investors, further aligning its portfolio with core banking priorities. The company also pursued strategic simplifications in its Home Lending business by exiting the Correspondent business and reducing the size of its Servicing portfolio, enabling a more focused mortgage operation targeting bank customers.

In 2021, Wells Fargo completed several major divestitures, including the sale of its Asset Management business to GTCR and Reverence Capital Partners, Corporate Trust Services to Computershare, and the Canadian Direct Equipment Finance business to TD Bank, allowing Wells Fargo to concentrate on core consumer and corporate clients. In 2019, Wells Fargo sold its Institutional Retirement & Trust business to Principal Financial Group, and it divested its auto finance segment in Puerto Rico to Popular, Inc. in 2018.

Together, these simplification efforts are expected to reduce operational costs, improve capital efficiency, and enable Wells Fargo to redeploy resources toward higher-return areas, strengthening its long-term growth prospects.

WFC’s Impressive Capital Distribution PlanWells Fargo has an impressive capital distribution plan. After clearing the Federal Reserve’s 2025 stress test, the company raised its common stock dividend by 12.5% in July 2025, to 45 cents per share.  It has raised its dividends six times in the past five years with an annualized growth rate of 29.3%. Bank of America raised its dividends five times over the past five years while Citigroup raised its dividends three times in the past five years.

Wells Fargo also has a share repurchase program in place. In April 2025, its board of directors authorized an additional $40 billion share repurchase program, following the $30-billion authorization announced in July 2023. As of Dec. 31, 2025, the company had remaining authority to repurchase up to $29.7 billion of common stock. 

As of Dec. 31, 2025, Wells Fargo’s long-term debt was $174.7 billion. However, short-term borrowings were $251 billion. The company has a strong liquidity position, with a liquidity coverage ratio of 119% as of Dec. 31, 2025, which has exceeded its regulatory minimum of 100%. Its liquid assets (including cash and due from banks, as well as interest-earning deposits with banks) totaled $174.2 billion as of the same date.

Given its robust capital position and ample liquidity, the company’s capital-deployment activities seem sustainable.

WFC’s Estimates & Valuation AnalysisThe Zacks Consensus Estimate for WFC’s 2026 and 2027 earnings indicates 9.9% and 12.8% year-over-year rallies, respectively. Estimates for both years have been revised downward over the past month.

Estimate Revision Trend

Image Source: Zacks Investment Research

In terms of valuation, the WFC stock appears inexpensive relative to the industry. The company is currently trading at a 12-month trailing price-to-earnings (P/E) ratio of 12.71X, which is lower than the industry’s 14.29X. Meanwhile, Citigroup holds a P/E ratio of 11.28X, while Bank of America’s P/E ratio stands at 12.30X.

Price-to-Earnings F12M

Image Source: Zacks Investment Research

Conclusion: Hold WFC Stock for NowWells Fargo has made significant progress in reshaping its business, and the removal of the asset cap marks a major turning point. Improved balance-sheet flexibility, disciplined expense management, business simplification and steady capital returns all strengthen its long-term outlook. Additionally, projected earnings growth for 2026 and 2027 and a valuation below the industry average suggest that the stock is reasonably priced.

That said, a significant portion of the positive momentum seems already priced in following the recent rally. Downward revisions to earnings estimates over the past month and the prospect of elevated expenses in the near term could temper short-term performance.

Given this balanced risk-reward profile, existing investors may consider holding on to the WFC stock to benefit from continued operational improvements and capital distributions. Prospective investors, however, may prefer to wait for a more compelling entry point or improved earnings visibility before taking a position.

Wells Fargo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Influential crypto traders Trader Mayne and DonAlt maintain a cautious, bearish-to-neutral stance on Bitcoin (CRYPTO: BTC), warning that a sharp V-shaped recovery is unlikely. ‘Slow, Grinding' Correction Ahead In their latest podcast, both analysts said they expect a prolonged, choppy correction rather than an immediate rebound.

OKX Ventures backed STBL to launch a stablecoin powered by real-world private credit investments. Institutions gain compliant, yield-generating digital cash. OKX Ventures, the investment division of the OKX crypto exchange, has invested in STBL, which is a company building a stablecoin backed by real-world assets. This deal brings in two major traditional finance partners, such as Hamilton Lane, a global private market firm, and Securitize, a regulated tokenization provider. These crypto firms and traditional finance companies together plan to launch a new kind of stablecoin on the X Layer, which is an OKX blockchain.

What is built into this deal This deal aims to move the stablecoins beyond simple cash by connecting them directly to institutional private credit investment. The project has access to Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE), which is a private credit strategy available to large institutional investors. Securitize will handle the legal issuance and tokenization, which makes sure that the product fits within the regulatory rules. 

STBL argues that tokenization must be useful and work inside the real financial system instead of sitting on the blockchain. So the company is building a system where the tokenized assets can be used for payments and settlements, for collateral, and for the company’s treasury management. 

Avtar Sehra, CEO of STBL, said that the market is moving beyond testing and experimenting, and right now, real functionality matters. Big investors will join if everything is regulated and legal. Reeve Collins, co-founder of STBL, is well known for helping build early stablecoin systems that connect crypto markets with traditional money. 

Big institutions are interested in blockchain, as it is faster and cheaper. But they also want proper rules and safe custody. OKX is combining with Hamilton Lane for managing big investments and securitizing for the legal and regulatory structure, which aims to create a product that connects DeFi and traditional financial markets. The announcement comes as banks and crypto firms increasingly focus on real-world asset tokenization. So firms are merging Wall Street products with the crypto rails.

Highlighted Crypto News: Thailand Approves Crypto as Underlying Assets in Markets